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Abstract 
Background 
Gram-negative bacilli bacteremia is a significant and rapidly developing problem in the 
United States.  Over 250,000 cases of gram-negative bacilli bacteremia occur each year in the 
United States, and recent data suggests that this number is rising.  A similarly significant and 
rapidly developing issue is the emergence of multi-drug resistant organisms.  First reported in the 
United States in 1989, multi-drug resistant gram-negative bacilli now comprise 22-54% of the 
causative agents of gram-negative bacilli bacteremia, depending on the hospital setting.  In this 
study, we determined the effect of multi-drug resistance on all-cause mortality, ICU admission, 
and duration of hospitalization. 
 
Methods 
A secondary data analysis was conducted using an existing data set that was compiled in 
a prospective cohort study from 2002-2009.  600 adult patients from Duke University Hospital 
with gram-negative bacilli bacteremia were stratified into three cohorts based on their drug 
susceptibility patterns. Univariate and bivariate analyses were then conducted comparing the 
cohorts and the outcomes of all-cause mortality (primary), ICU admission (secondary), and 
duration of hospitalization (secondary). 
 
Results 
The three sensitivity cohorts were comparable on all demographic and comorbidity 
characteristics.  Recent antibiotic use was 1.7-fold more common among patients in the multi-
drug resistant cohort than among patients in the pan-sensitive cohort (p=0.002).  All-cause 
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mortality for the entire sample was 15.3%.  Compared with the pan-sensitive cohort, risk ratios 
for all-cause mortality for the ESBL and multi-drug resistant cohorts were 1.12 (95% CI [0.66, 
1.89]) and 1.57 (95% CI [0.89, 2.77]), respectively (p=0.185).  ICU admission was required for 
21.8% of the sample.  Compared with the pan-sensitive cohort, risk ratios for ICU admission for 
the ESBL and multi-drug resistant cohorts were 1.23 (95% CI [0.79, 1.92]) and 1.81 (95% CI 
[1.13, 2.88]), respectively (p=0.020). Adjusted mean duration of hospitalization for the pan-
sensitive, ESBL, and multi-drug resistant cohorts were 15.6 days (95% CI [11.1, 20.1]), 17.7 
days (95% CI [14.9, 20.4]), and 26.9 days (95% CI [22.7, 31.2]), respectively (p<0.001). 
 
Conclusions 
The data from this study shows that multi-drug resistance does not confer any additional 
mortality on patients with gram-negative bacteremia over those with pan-sensitive or ESBL-
producing pathogens.  However, multi-drug resistance is associated with a 1.8-fold increased rate 
of ICU admission and an 11.3-day increased duration of hospitalization over patients infected 
with a pan-sensitive pathogen.  In light of these findings, care should be taken to reduce the 
spread of multi-drug resistance and reduce the amount of time patients with multi-drug resistant 
gram-negative bacteremia have to wait before they are treated with effective antibiotic therapy.   
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Introduction 
Gram-negative bacteremia is a significant and rapidly developing problem in the United 
States.  The most recent nationwide data (from 2000) indicates that over 660,000 cases of sepsis 
occur each year, with gram-negative organisms comprising approximately 250,000 cases 
(37.6%).1 Bacteremia is a significant issue within the hospital setting, in particular, as primary 
blood-stream infections account for 15-20% of all nosocomial infections.2 While gram-negative 
organisms were the primary causative agents in bacteremia prior to 1980, the emergence of 
methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative Staphylococcus 
(due to increasing rates of implanted devices in patients) in the 1980s and 1990s led gram-
positive organisms to become the primary causative agent of all blood-stream infections.3 
However, a prospective cohort study from the Hospital of the University of Pennsylvania 
published in 2006 notes that the proportion of blood-stream infections due to gram-negative 
organisms increased by 8.2% from 1999-2003.3 The study also notes that the overall incidence of 
blood-stream infections did not change significantly throughout the course of the study. This 
indicates that gram-negative bacteremia is becoming an increasingly significant threat. 
A similarly significant and rapidly developing issue is the emergence of multi-drug 
resistant organisms.  Despite initiatives across the nation to improve infection control and 
appropriate utilization of antibiotics, multi-drug resistance of gram-negative organisms has 
increased from 0% of nosocomial infections in 1990 to 26% in 2009.4-7 Resistance to extended-
spectrum beta-lactams (ESBLs) has seen a similar increase.  According to the National 
Nosocomial Surveillance System (NNIS) report in 2003, ESBL-producing K. pneumoniae 
isolates increased in proportion to the total number of K. pneumoniae isolates in intensive care 
units nationwide by 47% between 2002 and 2003 – from 6.1% of K. pneumoniae isolates in 2002 
 Page 5 of 38 
to 9.0% in 2003.8, 9 On non-intensive care wards, the rate of increase was similar (38% - from 
5.7% of K. pneumoniae isolates in 2002 to 7.9% in 2003).9 This increase appears small, but 
given the fact that in 2003 over 7,500 cases of K. pneumonia were reported to the NNIS, the 
increase in ESBL-producing isolates involves an additional 165-230 patients per year.9 This is 
both a clinically and statistically significant increase in resistance.  More recent nationwide data 
is unavailable, but prospective and retrospective cohort studies conducted through the late 2000s 
indicated that ESBL-producing organisms may be responsible for 20-30% of K. pneumoniae 
bacteremia cases.10 Given that ESBL-producing organisms were first reported in the United 
States in 1989, they have quickly emerged as a significant problem. 
Despite advances in clinical care, in-hospital mortality from gram-negative bacteremia 
has persisted at around 17-22% for the past three decades.1, 4, 11-13 Due to the many exotoxins and 
lipopolysaccharide endotoxins produced by Enterobacteriacea species, Enterobacteriacea 
bacteremia can cause rapid decompensation and is associated with a relatively high mortality 
rate.14 In a 2008 study of the impact of empiric therapy on outcomes in patients with 
Enterobacteriacea bacteremia from the University of Maryland Medical Center, an overall in-
house mortality of 17% was attributed to gram-negative sepsis.15 A 1994 study of gram-negative 
sepsis at the University of Iowa Hospitals and Clinics demonstrated even greater mortality 
among SICU patients (as one might expect), with an attributable in-hospital mortality of 35%.16  
Perhaps most concerning is the lack of focus on new antibiotic research and development 
for the treatment of gram-negative bacilli.  With the emergence of MRSA in the last two decades 
and the increased profitability of non-antibiotic medications, the pharmaceutical companies have 
shifted their focus to developing new drugs to treat gram-positive organisms, cardiovascular 
disease, renal disease, etc. However, recent evidence of the emergence of multi-drug resistant 
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gram-negative bacilli has yet to spur any action from pharmaceutical companies.  Given the fact 
that new drugs take at least ten years to get to the market, morbidity and mortality from multi-
drug resistant gram-negative bacilli bacteremia will likely increase significantly before the issue 
is adequately addressed.  Although introducing new antibiotics to the market is not a cure-all for 
the problem of increasing resistance - in fact, if infection control practices are not changed and 
antibiotic overuse minimized, new antibiotics will not affect resistance patterns – it is 
nevertheless a necessary component of treating patients with resistant organisms and reducing 
the recurrence of resistant bacteremia. 
 
Mechanisms of Resistance 
The outer lipopolysaccharide membrane of Enterobacteriacea species leads to a 
significant amount of resistance to conventional antibiotics.17 A combination of antibiotic 
overuse, inadequate treatment time, and the genetic transferability of bacterial resistance 
plasmids has resulted in increasing rates of multidrug-resistant Enterobacteriaceae species, 
particularly in hospital settings.18 The most significant increase in virulence factors in the past 20 
years has been seen among extended-spectrum beta-lactamases (ESBL), which first appeared in 
the United States in 1988 and are now found in 75% of medical centers in the United States.9 
According to a study of 77-117 ICUs (not all ICUs participated each year) representing 43 states 
in the US, Klebsiella pneumonia isolates’ susceptibility to third-generation cephalosporins 
(which were designed to treat bacteria that had beta-lactamase virulence factors) fell by 6% from 
1994-2000.19 
Although the question of whether or not multi-drug resistance itself confers any 
additional mortality upon patients remains inconclusively answered, multi-drug resistance is 
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associated with inadequate empiric therapy.13, 17 In turn, inadequate empiric therapy is associated 
with a 7-18% increase in mortality, depending on the Enterobacteriaceae species with which the 
patient is infected.13, 17 Even when adjusting results for differences in patient comorbidities and 
demographic characteristics at baseline, inadequate empiric therapy is associated with increased 
mortality.20 This is because timely administration of adequate antibiotic therapy is an important 
factor in reducing mortality secondary to gram-negative sepsis.13 Distinguishing patients with 
multi-drug resistant Enterobacteriacea bacteremia from those infected with susceptible species 
can help us better understand these organisms and their effect as infectious agents. 
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Systematic Review of the Literature 
 I conducted a brief systematic review of the literature to determine what effect multi-drug 
resistance has had on morbidity and mortality in other studies. 
 
Selection of Articles 
 In order to identify the relevant literature for this paper, I searched the MEDLINE 
database in April 2010.  I used the following MeSH terms in the search: “Enterobacteriaceae,” 
“Bacteremia,” “Drug Resistance, Multiple.”  96 articles resulted from this search.  At the 
direction of the UNC Health Sciences librarian Mellanye Lackey, I conducted a Google Scholar 
search with the following terms: “Multidrug Resistant,” “Bacteremia,” and “Gram-Negative 
Bacilli OR Enterobacteriaceae.”  588 additional articles were found using this search technique.  
Dr. Vance Fowler provided an additional 8 articles from his files. 
 I reviewed abstracts from each of the articles from these initial searches.  The articles 
selected from the initial pool of studies were selected based on a set of criteria.  Studies had to be 
written in English, include patients 18 years of age and older, and include patients of all 
demographic groups. Studies were excluded from the review if they did not pertain to gram-
negative bacteremia or antibiotic resistance.  However, I did not exclude studies that pertained to 
ESBL-producing gram-negative pathogens, as this represents one of our sensitivity cohorts in 
this study. Studies were not excluded if they had alternative definitions of multi-drug resistance 
so long as they clearly stated what definition was used in the study.  Studies also had to have an 
outcome of mortality, although the studies did not have to pertain to either of the secondary 
outcomes of this study (duration of hospitalization or ICU admission). I excluded case reports 
and editorials from review. 
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 Although there is a decent amount of literature on multi-drug resistance, few studies 
analyze the relationship between multi-drug resistance and mortality and instead measure the risk 
factors for multi-drug resistance.  Alternatively, studies analyze the relationship between multi-
drug resistance and inadequate initial antibiotic therapy independent of mortality. As a result, 
only 5 articles met the criteria for inclusion in the literature review. 
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of the reviewed articles: studies of the association between multi-drug 
resistance and mortality in patients with gram-negative bacteremia. 
First 
Author 
Title Design Source and 
Sample 
Populations 
Drug 
Resistance 
Definitions 
Study 
Outcomes 
Results 
Blot21 Nosocomial 
bacteremia 
caused by 
antibiotic-
resistant gram-
negative bacteria 
in critically ill 
patients: clinical 
outcome and 
length of 
hospitalization 
Retrospect
ive cohort 
study 
Source – 
29,727 ICU 
patients in 
Ghent, 
Belgium 
from 1992-
2000. 
Sample – 328 
patients with 
gram-
negative 
bacteremia 
“Antibiotic 
Resistant” = 
resistant to 
ceftazidime 
and one of 
the 
following: 
piperacillin, 
ciprofloxaci
n, or 
imipenem 
In-hospital 
mortality and 
duration of 
hospitalizatio
n 
Antibiotic 
resistance is not 
associated with 
increased 
mortality, but is 
associated with 
a 13-day 
increase in 
duration of 
hospitalization 
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Kang20 Bloodstream 
infections caused 
by antibiotic-
resistant gram-
negative bacilli: 
risk factors for 
mortality and 
impact  
Retrospect
ive cohort 
study 
Source – 
1917 patients 
in Seoul, 
ROK with 
gram-
negative 
bacilli 
bacteremia  
from 1998-
2002. 
Sample – 286 
patients with 
antibiotic-
resistant 
bacteremia  
“Antibiotic 
Resistant” = 
resistant to 
ceftazidime 
or 
cefotaxime 
and one of 
the 
following: 
piperacillin, 
ciprofloxaci
n, or 
imipenem 
Identify risk 
factors for 
mortality and 
the effect of 
inappropriate 
initial 
antimicrobial 
therapy on 
mortality  
Inappropriate 
initial antibiotic 
therapy is 
associated with 
3.6-fold 
increase in 
mortality.  
APACHE II 
score associated 
with 1.3-fold 
increase in 
mortality per 1-
point 
increment. 
Peralta17 Impact of 
antibiotic 
resistance and of 
adequate 
empirical 
antibiotic 
treatment in the 
prognosis of 
patients with 
Escherischia coli 
bacteraemia 
Retrospect
ive cohort 
study 
Source – 
15,045 
inpatients 
who had 
blood 
cultures in a 
Torrelavega, 
Spain 
hospital from 
1997-2005. 
Sample – 663 
patients with 
E. coli 
bacteremia 
MDR E. 
coli = 
resistant to 
3+ of the 
following: 
amoxicillin/
clavulanate, 
cefotaxime 
or 
ceftazidime, 
ciprofloxaci
n, 
gentamicin, 
piperacillin/
tazobactam, 
and 
trimethopri
m/sulfameth
oxazole 
All-cause 
mortality, 
duration of 
hospitalizatio
n, and 
adequacy of 
empiric 
antibiotic 
therapy 
MDR E. coli 
associated with 
3.3-fold 
increase in 
mortality, 5-day 
increase in 
duration of 
hospitalization, 
and 1.9-fold 
decrease in 
adequacy of 
empiric 
antibiotic 
therapy  
Cheong22 Bacteremia due 
to quinolone-
resistant 
Escherischia coli 
in a teaching 
hospital in South 
Korea 
Retrospect
ive case-
control 
Source – 
Patients 
admitted to a 
Seoul, ROK 
hospital from 
1993-1998 (# 
unknown). 
Sample – 120 
patients with 
E. coli 
bacteremia 
 
Multi-drug 
resistance = 
resistance to 
≥ 3 classes 
of antibiotic 
agents other 
than 
fluoroquinol
ones 
In-hospital 
mortality and 
duration of 
hospitalizatio
n 
No association 
between multi-
drug resistance 
and mortality, 
but a 3-day 
increase in 
duration of 
hospitalization 
was observed. 
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Hyle23 Impact of 
inadequate initial 
antimicrobial 
therapy on 
mortality in 
infections due to 
extended-
spectrum ß-
lactamase-
producing 
Enterobacteriace
ae 
Retrospect
ive cohort 
study 
Source – 
Patients 
admitted to 
either of 2 
hospitals in 
Philadelphia, 
PA for 
Enterobacteri
acae 
infection 
between 
1997 and 
2002. 
Sample – 187 
patients 
infected with 
ESBL-
producing 
Enterobacteri
aceae 
ESBL = 
resistant to 
ampicillin 
and 2nd and 
3rd 
generation 
cephalospor
ins 
MDR = 
resistance to 
the above 
antibiotics/c
lasses and 
trimethopri
m/sulfameth
oxazole, 
aminoglyco
sides, and 
fluoroquinol
ones 
In-hospital 
mortality and 
inadequate 
initial 
antimicrobial 
therapy 
MDR is 
associated with 
a 14.6-fold 
increase in 
inadequate 
initial 
antimicrobial 
therapy.  
Inadequate 
initial 
antimicrobial 
resistance is 
associated with 
a 2.3-fold 
increase in in-
hospital 
mortality. 
 
Table 1 presents a summary of the five articles reviewed, including the populations from 
which the study drew, the key definitions for multi-drug resistance, the study outcomes, and any 
significant findings that pertain to our study.  As evidenced in Table 1, the literature varies on the 
relationship between multi-drug resistance and mortality, as several studies demonstrated no 
significant association and at least one study demonstrated a statistically and clinically 
significant increase in mortality with the multi-drug resistant cohort.  The literature does appear 
to agree that multi-drug resistance is associated with inadequate initial antibiotic therapy, which, 
in turn, is associated with increased mortality.  Furthermore, the literature agrees that multi-drug 
resistance prolongs the duration of hospitalization, though the amount of prolongation varies 
between 3 days and 13 days. 
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Appraisal of the Literature 
Table 2 contains a quantitative quality rating of each of the above studies.   
Table 2. Final Quality Ratings Table.  Each study was rated 0-3 for each category (0=poor, 
1=fair, 2=good, 3=excellent). 
First Author Source and 
Sample 
Populations 
Adequately 
Described? 
Cohorts 
or Cases 
and 
Controls 
are 
Similar 
at 
Baseline? 
Adequate 
Description 
of 
Measurement 
Tool? 
Appropriate 
Analysis? 
Results 
Reported 
Adequately? 
External 
Validity? 
Overall 
Quality 
Score (0-
18) 
Blot21 1 0 2 2 3 0 8 
Kang20 2 2 2 2 3 2 13 
Peralta17 2 3 3 2 3 2 15 
Cheong22 0 0 2 2 3 0 7 
Hyle23 1 0 2 3 3 1 10 
 
The following is a detailed account of how each category was graded (poor to excellent). 
 
Articles’ Source and Sample Populations 
 The source and sample populations for each of the studies varied significantly in 
accordance with the goals of each study.  Although I sought articles with a source population of 
admissions at a teaching hospital over a several-year time span and a sample population of 
patients admitted with gram-negative bacilli bacteremia in accordance with the populations of 
our own study, this was not feasible.   
As evidenced by Table 2, I assigned two of the articles a “good” rating for description of 
populations, two articles a “fair” rating, and one article a “poor” rating.  In order to be given a 
“good” rating, the studies by Kang et. al. and Peralta et. al. defined the population and time 
frame from which the they drew their sample, stated how the sample population was determined, 
and gave a detailed description of the demographic characteristics of their sample.  Blot et. al. 
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and Hyle et. al. were given “fair” ratings because although they clearly defined their populations, 
they did not provide adequate demographic characteristics.  I gave Cheong et. al. a “poor” rating 
because the source population was not well defined and the author does not describe how the 
controls for the sample population were determined. 
 I also assigned the articles a grade based on how similar the cohorts or cases and controls 
were at baseline.  This was done to ensure that selection bias was minimized and to identify any 
potential confounders.  Peralta et. al. received an “excellent” rating because the two cohorts were 
demographically similar and the only statistically significant difference between the cohorts was 
whether or not the patients were “post-surgical,” and the low number of patients in each cohort 
leads me to believe that this difference was not necessarily clinically significant.  Kang et. al. 
received a “good rating” because most of the demographic and comorbidity characteristics were 
similar between the two cohorts and the only clinically significant differences were in the 
causative organisms of infection.  These differences were profound and have the potential to 
greatly confound the results. 
 Cheong et. al. received a “poor” rating for the similarity of cases and controls because 
there were several statistically and clinically significant differences between the two groups in 
demographic and comorbidity characteristics, as well as in the source of bacteremia.  I gave Blot 
et. al. and Hyle et. al. “poor” ratings because they failed to disclose demographic and 
comorbidity characteristics at baseline, so no cohort comparisons could be made. 
 
Articles’ Measurements 
 The articles reviewed were also given a quality rating for their measurement techniques 
and the description of those measurements.  I gave Peralta et. al. a rating of “excellent” for their 
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measurement techniques and description of the same because their definitions for comorbid 
conditions and susceptibilities were extremely detailed and referenced the basis for their 
definitions and their measurement techniques and practices were standardized so as to minimize 
bias.  Blot et. al., Kang et. al., and Cheong et. al. all appeared to have standardized measurement 
techniques and clearly defined descriptions of the measurement techniques and definitions they 
used in their study, but some of their definitions appeared arbitrary, so I assigned each a rating of 
“good.”  Hyle et. al. received a rating of “good” despite the study’s standardized measurement 
techniques and evidence-based definitions because the hospitals changed their methods for 
susceptibility testing halfway through the study, which could introduce some bias. 
 
Articles’ Analysis and Results 
 Articles were appraised based on the quality of their analysis and manner in which the 
results were reported.  Hyle et. al. was the only article to which I assigned a rating of “excellent” 
in both categories.  The primary difference between the Hyle et. al. analysis and the analysis of 
the other four articles was the adjustment that Hyle et. al. made for potential confounders.  Not 
only did Hyle et. al. adjust for confounders that had a statistically significant impact on the 
results, they factored in the Bonferonni correction and included all confounders whose 
association with the outcome was p<0.2 rather than p<0.5.  Although Blot et. al. alluded to 
adjusting for confounding variables, it was not explicitly stated.  All other studies received a 
rating of “good” for the analysis because the statistical tests used were appropriate and clearly 
stated. 
 All five articles received a quality rating of “excellent” for the manner in which results 
were reported.  In order to receive a rating of “excellent,” studies had to present the primary 
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findings of the study in an easily readable format and explicitly state the certainty of their results 
through the statistical significance.  Furthermore, studies had to discuss the clinical significance 
of their findings.  All of the articles met the criteria for an “excellent” rating in this category. 
 
Articles’ External Validity 
 The final quality rating assessed in this systematic review was the overall external 
validity of the results.  Each article was given a quality rating based on whether the results of the 
study could be generalized to a broader population than the source population, particularly to a 
population similar to the population in our own study.  Given that each of these studies was 
retrospective in nature, the post-test effect limits the generalizability of all five studies and so no 
“excellent” ratings were awarded. 
 I assigned Kang et. al. and Peralta et. al. a quality rating of “good” for their external 
validity.  Despite the fact that their studies took place in South Korea and Spain, respectively, the 
hospitals were tertiary teaching centers and so I believe that these results could be pertinent to 
our study.  Hyle et. al. received a “fair” rating because one of the study sites was a US teaching 
hospital, similar to the site of our own study.  However, the lack of data on cohort comparisons 
and the fact that the methods for determining susceptibilities changed halfway through the study 
reduces the generalizability of these results. 
 Blot et. al. and Cheong. et. al. each received “poor” ratings for their external validity.  
Both studies occurred more than 10 years ago, and given the ever-changing nature of drug 
resistance, it is difficult for me to conclude that the results of these studies could be generalized 
to our population.  Furthermore, Blot et. al. was a study dealing exclusively with ICU patients, so 
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while the results are helpful in understanding how multi-drug resistance effects patients once 
they require intensive care, the results cannot be generalized to our study. 
 
Summary of the Critical Appraisal 
 Although this is only a summary of the findings, it is evident that a gap in the literature 
exists, as the results are relatively inconclusive and none of these articles are prospective cohort 
studies.  Prospective cohort studies add a new facet to the literature because they enable greater 
control over the study design and outcome measurement within the study.  Although several of 
the above studies were well-designed and executed, it is clear that further research is required in 
this field. 
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Methods 
Study Setting and Population 
I conducted a secondary data analysis using an existing data set that was compiled in a 
prospective cohort study conducted during 2002-2009.  All clinical data for this cohort of 
subjects were previously collected under IRB-approved protocol #Pro00008031.  Subjects were 
selected from patients treated at Duke University Hospital in Durham, North Carolina, from 
2002-2009 in compliance with Health Insurance Portability and Accountability Act (HIPAA). 
Existing Institutional Review Board (IRB)-approved (#1602-02-8R3ER now changed to #1048-
05-6R7), HIPAA compliant procedures were used to categorize bloodstream gram-negative 
isolates for the bacterial studies. Each workday, the Medial Technician working on the Blood 
culture bench of the Duke Clinical Microbiology Laboratory (DCML) notified the study 
coordinator or research assistant of all patients at DUMC with at least one blood culture positive 
for gram-negative bacilli. This system allowed immediate notification of potential subjects with 
gram-negative bacilli bacteremia. This system has been in place since 1994, is highly reliable, 
retains the strong support of the Clinical Microbiology Laboratory, and has been granted Waiver 
of Consent and HIPAA Authorization by the Duke IRB. Research personnel evaluated all 
persons identified with gram-negative bacilli bacteremia on weekends and holidays on the 
morning of the next workday to determine whether the patient met study criteria. Research 
personnel determined the patients’ eligibility using criteria (below), then contacted the patients’ 
physician (preferably the attending) for permission to approach the patient about study 
participation. 
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Table 3. Inclusion and Exclusion Criteria for Patients in this Study. 
Inclusion Criteria Adults (18+ years) with culture-confirmed bloodstream infection. 
Patients with bloodstream infection transferred to DUMC are 
eligible if pathogen speciation and antibiotic susceptibilities are 
confirmed by the DCML. 
 
 Patient or patient’s legally authorized representative provides signed 
informed consent allowing participation, unless patient expires prior 
to notification of blood culture results. In this instance, human DNA 
and RNA samples, clinical data, and the bacterial isolate from the 
subject are cataloged using an IRB-approved Notification of 
Decedent Research. 
 
Exclusion Criteria Prior enrollment of patient in this investigation (to ensure statistical 
independence of observations). 
 
 Bloodstream infection that is not confirmed by culture and 
speciation at the DCML. 
 
 Outpatient status 
 
 Polymicrobic 
 
 Neutropenic 
 
 Pediatric (Age must be greater than 18 years.) 
 
 
 Table 3 presents the inclusion and exclusion criteria for enrollment in this study.  In total, 
649 patients were enrolled in the study and added to the database at the time of analysis (April 
2010).  49 patients were excluded from the analysis because sensitivities were not included in 
their data set and so they could not be assigned to a cohort. 
 
Cohort Stratification 
I stratified patients into cohorts by drug resistance patterns.  The eight antibiotic classes 
and/or subclasses used to determine susceptibility were basic beta-lactams (ampicillin), 1st 
generation cephalosporin (cefazolin), 3rd generation cephalosporin (ceftriaxone), synthetic anti-
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pseudomonal penicillin (piperacillin), carbapenem (imipenem), aminoglycoside (gentamicin), 
fluoroquinolone (ciprofloxacin), and sulfonamides (trimethoprim-sulfamethoxazole).  I assigned 
all patients susceptible to all eight drugs/drug classes into the first “pan-sensitive” cohort, all 
patients susceptible to beta-lactams and cephalosporins into the second “ESBL” group, and 
patients susceptible to greater than 2 drugs/drug classes into the “multi-drug resistant” group.  
The delineation of 3 drugs/drug classes as the starting point of “multi-drug resistance” is in 
accordance with the preponderance of the literature.6, 7, 17, 24-29 Duke University Hospital’s 
susceptibility reporting guidelines and preferred therapy dictated which drugs represented each 
drug class.  In assessing antibiotic resistance profiles, I counted resistance to any number of 
cephalosporins as one resistance character to avoid double-counting resistance to both 1st and 3rd 
generation cephalosporins. 
 
Statistical Analysis 
 Prior to receipt of the database for statistical analysis, the Infectious Disease Database 
Coordinator removed all identifiers such as names and medical record numbers from the data set 
in order to protect the patients’ privacy.  I conducted an analysis of the data using STATA 
(version 11).  I defined mortality to include all causes of mortality, as the duration of data 
collection in this study precludes any analysis of attributable mortality.  I defined the secondary 
outcome of “ICU admission required” as any patient who was admitted to the ICU after being 
enrolled in the study.  I measured the secondary outcome of “duration of hospitalization” as days 
from admission to discharge, not from enrollment in the study to discharge. 
 In order to calculate the overall prevalence of each outcome, I conducted univariate 
analyses.  I also conducted bivariate analyses to assess differences in outcome based on the three 
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sensitivity cohorts descried above.  For a more tangible assessment of the outcome variables, I 
calculated risk ratios for all-cause mortality and ICU admission based on sensitivity cohort.  For 
this analysis, I compared the ESBL and multi-drug resistant cohorts with the pan-sensitive 
cohort, and the risk ratio represents that comparison.  Finally, I calculated the probabilities of 
each outcome, stratified by sensitivity cohort.  I adjusted this calculation by the APACHE II 
score on admission so as to account for any potential confounding from the severity of illness on 
admission. 
 For the purposes of this study, I analyzed nominal outcomes (mortality and ICU 
admission) using Pearson’s Chi-Squared Test.  Using the one-way analysis of variance 
(ANOVA) test, I analyzed the continuous outcome of duration of hospitalization.  I used Fisher’s 
Exact Test in place of Pearson’s Chi-Squared Test when comparing cohorts among themselves to 
calculate risk ratios due to the relatively small sample size. 
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Results 
Table 4. Selected Characteristics for a Cohort of Adults with Gram-Negative Bacteremia at 
Baseline 
Characteristic Overall 
mean (SD) 
or number 
(%) 
(n=600) 
Pan-sensitive 
mean (SD) or 
number (%) 
(n=125) 
ESBL mean 
(SD) or 
number (%) 
 (n=336) 
Multi-drug 
resistant mean 
(SD) or number 
(%)  
(n=139) 
Age in years 58.1 (16.1) 58.9 (17.2) 57.6 (15.6) 58.8 (14.2) 
Gender     
     Male 322 (53.7) 59 (47.2) 185 (55.1) 78 (56.1) 
     Female 278 (46.3) 66 (52.8) 151 (44.9) 61 (43.9) 
Race     
     White 405 (67.5) 79 (63.2) 227 (67.8) 99 (71.2) 
     Black 163 (27.2) 39 (31.2) 90 (26.9) 34 (24.5) 
     Hispanic 4 (0.7) 1 (0.8) 3 (0.9) 0 (0.0) 
     Native American 6 (1.0) 1 (0.8) 4 (1.2) 1 (0.7) 
     Other 21 (3.5) 5 (4.0) 11 (3.3) 5 (3.6) 
Comorbidities     
     Diabetes Mellitus type II 183 (30.5) 42 (33.6) 97 (29.0) 44 (32.1) 
     Corticosteroid use in the past 
30 days 
149 (24.8) 33 (26.6) 73 (22.1) 43 (31.4) 
     Neoplasm 238 (39.7) 47 (37.6) 137 (41.1) 54 (39.7) 
     HIV positive 9 (1.5) 3 (2.4) 2 (0.6) 4 (2.9) 
     Surgery in the past 30 days 192 (32.0) 34 (28.1) 111 (33.4) 47 (34.1) 
Antibiotic use in the past 30 days 234 (39.0) 36 (30.0) 128 (38.7) 70 (51.5)* 
Total Apache II score on 
admission 
14.3 (6.5) 15.0 (6.5) 14.0 (6.1) 14.6 (6.6) 
     Acute physiologic score 7.5 (5.5) 8.0 (5.6) 7.3 (5.2) 7.5 (5.7) 
     Age points 3.1 (2.1) 3.2 (2.2) 3.0 (2.0) 3.2 (2.0) 
     Chronic health points score 3.7 (2.0) 3.8 (1.9) 3.6 (2.1) 3.8 (2.0) 
*p<0.05 
 
The characteristics of each of the three sensitivity cohorts and the entire study population 
(n=600) were examined at baseline (Table 4). In this study sample, the average age of patients 
enrolled with gram-negative bacteremia was 58.1, there were slightly more men than women 
enrolled (53.7% v. 46.3%), and almost 95% of patients were either white or black (67.5% and 
27.2%, respectively).  Comorbidities such as diabetes mellitus, recent corticosteroid use, 
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neoplasm, and recent surgery were prevalent within the sample, as between 25% and 40% of 
patients had one or more of these comorbidities.  Of note, the demographic data and 
comorbidities did not differ in a statistically significant or clinically significant manner among 
the three sensitivity cohorts.  Recent antibiotic use is more common among patients with multi-
drug resistant GNR bacteremia than among patients with ESBL or pan-sensitive gram-negative 
bacteremia (51.5% v. 38.7% v. 30.0%, respectively).  The difference here is statistically 
significant (p=0.002). Finally, the APACHE II score does not differ among any of the three 
sensitivity cohorts. 
 
Table 5. Outcome Variables among Cohorts 
Outcome Pan-sensitive 
mean (SD) or 
number (%) 
(n=125) 
ESBL mean 
(SD) or 
number (%) 
(n=336) 
Multi-drug resistant 
mean (SD) or 
number (%) 
(n=139) 
All-cause mortality 16 (12.8) 48 (14.3) 28 (20.1) 
ICU admission required 21 (16.9) 69 (20.9) 41 (30.6)* 
Duration of hospitalization 15.7 (25.2) 17.6 (21.7) 27.0 (33.4)* 
*p<0.05 
 
The primary outcome for this study was all-cause mortality.  Although mortality 
increased as resistance increased (12.8% pan-sensitive v. 14.3% ESBL v. 20.1% multi-drug 
resistant), this difference was not statistically significant (p=0.185). The two secondary outcomes 
measured in this study were ICU admission and duration of hospitalization.  As evidenced in 
Table 5, patients with multi-drug resistant gram-negative bacteremia were more likely to require 
ICU admission during their hospitalization than patients with ESBL or pan-sensitive gram-
negative bacteremia (30.6% v. 20.9% v. 16.9%, respectively).  This difference was statistically 
significant (p=0.02).  As far as duration of hospitalization is concerned, patients with multi-drug 
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resistant gram-negative bacteremia were more likely to require a longer hospitalization than 
patients with ESBL or pan-sensitive gram-negative bacteremia (mean 27.0 days v. 17.6 days v. 
15.7 days, respectively). This difference was statistically significant (p<0.001). 
 
Table 6. Risk Ratios for All-Cause Mortality Based on Sensitivity (Baseline – Pan-sensitive) 
Sensitivity Cohort Risk Ratio 95% CI 
ESBL 1.12 [0.66, 1.89] 
Multi-drug Resistant 1.57 [0.89, 2.77] 
 
 In order to develop a better understanding of the effects of multi-drug resistance on the 
two nominal outcomes, risk ratios were developed comparing the relative risk of all-cause 
mortality and ICU admission for the ESBL and multi-drug resistant cohorts against the pan-
sensitive cohort as the baseline.  As evidenced in Table 6, although the relative risk of all-cause 
mortality is higher for the ESBL and multi-drug resistant cohorts than it is for the pan-sensitive 
cohort (1.12 and 1.57, respectively), the 95% confidence interval shows that the results are not 
statistically significant. 
 
Table 7. Risk Ratios for ICU Admission Based on Sensitivity (Baseline – Pan-sensitive) 
Sensitivity Cohort Risk Ratio 95% CI 
ESBL 1.23 [0.79, 1.92] 
Multi-drug Resistant 1.81 [1.13, 2.88] 
 
 Although the risk ratios for all-cause mortality do not reflect any statistical significance, 
the risk ratios for ICU admission (Table 7) do.  The relative risk of ICU admission for patients 
with ESBL and multi-drug resistant gram-negative bacteremia, when compared against patients 
with pan-sensitive gram-negative bacteremia, is 1.23 and 1.81, respectively.  The 95% 
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confidence interval for the multi-drug resistant cohort shows that this relative risk is statistically 
significant. 
 
Table 8. Adjusted Probabilities and 95% Confidence Intervals for Outcomes Based on 
Sensitivity Cohort (Adjusted by APACHE II Score on Admission) 
Outcome Pan-sensitive 
probability [95% CI] 
ESBL probability 
[95% CI] 
Multi-drug resistant 
probability [95% CI] 
All-cause mortality 0.08 [0.04, 0.14] 0.11 [0.08, 0.15] 0.15 [0.10, 0.22] 
ICU admission required 0.15 [0.10, 0.22] 0.20 [0.16, 0.25] 0.29 [0.22, 0.37]* 
Duration of hospitalization 
– mean # days [95% CI] 
15.60 [11.11, 20.09] 17.67 [14.93, 20.41] 26.91 [22.66, 31.16]* 
*p<0.05 
In order to more accurately determine the probability of each outcome for each of the 
three sensitivity cohorts, an adjusted analysis was conducted to reduce confounding.  The 
APACHE II score was chosen to represent the severity of illness because it is a well-recognized 
indicator of the same.  Since the severity of illness can be related to the sensitivity pattern and 
impact the outcome, it is a potential confounder and the outcome probability should be adjusted 
to reflect that.  As evidenced in Table 8, even after adjusting for the severity of illness, there was 
still a statistically significant increase in the likelihood of ICU admission and the duration of 
hospitalization for the multi-drug resistant cohort when compared against the ESBL and pan-
sensitive cohorts (p=0.018 and p<0.001, respectively).  Patients with multi-drug resistant gram-
negative bacteremia are almost twice as likely (adjusted probability 0.29 v. 0.15) to require ICU 
admission than patients with pan-sensitive gram-negative bacteremia.  Moreover, patients with 
multi-drug resistant gram-negative bacteremia are likely to require 11 additional days of 
hospitalization when compared with patients with pan-sensitive gram-negative bacteremia (26.91 
days v. 15.61 days).  Although the probability of mortality (all-cause) for patients with multi-
drug resistant gram-negative bacteremia is almost twice that of patients with pan-sensitive gram-
 Page 25 of 38 
negative bacteremia (adjusted probability 0.15 v. 0.08), the difference is not statistically 
significant. 
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Discussion 
Cohort Comparisons 
 At baseline, the three sensitivity cohorts appear to be comparable in all demographic and 
comorbidity criteria (Table 4).  The mean or percentage of each of these criteria does not reflect 
any statistically significant or clinically significant difference between these cohorts, and each 
cohort is similar to the overall sample mean or percentage for each criteria.  There is a 
statistically and clinically significant increase in the percentage of patients in the multi-drug 
resistant cohort who had taken antibiotics in the last 30 days as compared to those in the ESBL 
or pan-sensitive cohort.  This is expected, as recent antibiotic use is a well-known risk factor for 
infection with resistant species.6, 9, 26, 28-33 
The severity of illness, as measured by the APACHE II score on admission, was not 
statistically or clinically significant among the three cohorts.  This indicates that the mere 
presence of genes for antibiotic resistance in an organism does not confer any additional 
pathogenicity.  As a result, any increased morbidity or mortality experienced by a patient with 
multi-drug resistant gram-negative bacteremia over someone with pan-sensitive gram-negative 
bacteremia is due to the delay in effective antibiotic therapy and not simply the presence of 
additional genetic material that confers resistance to antibiotics.34 
 Overall, the three sensitivity cohorts are comparable and there is no indication that 
confounding will bias the analysis. 
 
Primary Outcome: All-cause mortality 
 Cumulative all-cause mortality for the sample population was 15.3% (92/600).  Most 
studies have an all-cause mortality of 17-22%,1, 4, 11-13 but the preponderance of the literature 
 Page 27 of 38 
consists of retrospective cohort studies and chart reviews, where higher mortality rates are 
expected.  The all-cause mortality of 15.3% found in this study is consistent with the 16% all-
cause mortality rate for patients with culture-positive bacteremia found in M. Sigfridio Rangel-
Fausto’s 1995 prospective study on the natural history of SIRS.35 
 Although mortality increased as the degree of resistance increased among the cohorts, the 
difference was not statistically significant (Table 5).  Despite the 7.3% increase in mortality for 
the multi-drug resistant cohort over the pan-sensitive cohort (20.1% v. 12.8%, respectively) and 
risk ratio of 1.57 (95% CI 0.89, 2.77) for the same cohort comparison, it is difficult to attribute 
any clinical significance to this result either.  In order to do so, the sample size would have to be 
larger to increase the power of the study.  After adjusting for the initial severity of illness, the 
difference was still not statistically significant, so we cannot determine based on our sample 
population that infection with multi-drug resistant organisms confers any addition mortality on 
patients with gram-negative bacteremia. 
 
Secondary Outcome: ICU Admission Required 
 ICU admission rates for the entire sample population were 21.8% (131/600).  The 
Pearson’s Chi-Squared Test conducted in this study determined that there was a statistically 
significant increase in ICU admission for patients with multi-drug resistant gram-negative 
bacteremia than for patients with ESBL or pan-sensitive gram-negative bacteremia (30.6% v. 
20.9% v. 16.9%, respectively).  This is both statistically significant and clinically significant.  
Given the fact that multi-drug resistant organisms are less likely to be effectively treated with 
empiric antibiotic therapy than pan-sensitive organisms, there is a greater likelihood that 
effective antibiotic therapy will be delayed for patients with multi-drug resistant gram-negative 
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bacteremia.36 This delay in effective therapy leads to an overall increase in the severity of illness, 
and so an increase in ICU admission for the multi-drug resistant cohort is both reasonable and 
expected. 
  The fact that multi-drug resistant gram-negative bacteremia bears a relative risk of 1.81 
(95% CI 1.13, 2.88) of ICU admission as compared to pan-sensitive gram-negative bacteremia is 
concerning.  Not only does ICU care signify an increased severity of illness, it is also a risk 
factor for additional infections independent of the primary infection.3, 19 If a patient’s condition 
deteriorates to the point that they require care in the ICU, they are more likely to be exposed to 
the hardier, multi-drug resistant pathogens indigenous to ICU settings.  These pathogens confer 
additional morbidity, increase the duration (and cost) of hospitalization, and can lead to a higher 
mortality rate than those found outside of the ICU.3, 19, 37, 38 Therefore, it is in the best interest of 
the patient that the initial bloodstream infection be treated as quickly and effectively as possible 
in order to prevent ICU admission.   Unfortunately, the results of this study indicate that multi-
drug resistant pathogens are associated with higher rates of ICU admission. 
 
Secondary Outcome: Duration of hospitalization 
 The mean duration of hospitalization for the sample population was 19.4 days.  The 
ANOVA test conducted on the three sensitivity cohorts demonstrated a statistically significant 
increase in mean duration of hospitalization for the multi-drug resistant cohort when compared to 
the ESBL and pan-sensitive cohorts (mean 27.0 days v. 17.6 days v. 15.7 days, respectively).  
This increase in length of hospitalization is also clinically significant, as an extra 9.4 days or 11.3 
days (depending on the cohort to which we are comparing the multi-drug resistant cohort) adds a 
substantial burden of morbidity and mortality.  As with ICU admission, not only does a longer 
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hospital stay signify a slower recovery or worsening of the initial condition, it also exposes 
patients to healthcare-associated pathogens for a greater period of time, increasing the likelihood 
that the patient will develop a second infection independent of the primary infection.   
 Moreover, hospitalization is expensive.  As the duration of hospitalization – and 
consequently the likelihood of prolonging the hospitalization due to a secondary infection – 
increases, the costs rise exponentially.  Given the state of our economy and the necessary limits 
of insurance coverage, many of these costs are borne by the patient, the hospital, and the entirety 
of the insurance pool.  Therefore, it is in the best interest of society that the duration of 
hospitalization be kept as short as reasonably possible.  Unfortunately, the results of this study 
suggest that multi-drug resistance provides a barrier to earlier discharge.  
 
Public Health Impact 
The public health impact of multi-drug resistance in gram-negative bacteremia is 
substantial.  Although this study has not conclusively shown any statistically significant increase 
in mortality among patients in the multi-drug resistant cohort over patients in the ESBL and pan-
sensitive cohorts, the increased ICU admission rates and duration of hospitalization are a public 
health concern.  First of all, not only are patients with multi-drug resistant pathogens more likely 
to contract a secondary infection due to their increased duration of hospitalization and ICU 
admission rate, they are also in a confined setting where they can expose other patients – many 
of whom are likely immunocomprised – to multi-drug resistant pathogens.  This means that the 
increased resistance not only confers additional morbidity on the patients, but potentially on 
society as a whole. 
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Secondly, with the increasingly ambulatory nature of our health care system, pathogens 
(or resistance patterns) once endemic only to health care settings are becoming more prevalent in 
the community.39 As multi-drug resistance rates increase within the health care setting, so too do 
they increase in the community.  The results of this study indicating that multi-drug resistance is 
associated with prolonged hospitalization and increased likelihood of ICU admission do not 
mean that the more resistant pathogens will be confined to health care settings, but rather that the 
community is likely to experience an increase in multi-drug resistant pathogens. 
Although cost is a secondary concern to the effect of multi-drug resistance on morbidity 
and mortality, it is nevertheless a significant issue.  In 2003, The United States Office of 
Technology Assessment estimated that the national cost of antibiotic resistance was $4 billion 
per year in 1995 dollars ($5.7 billion in 2010 dollars).36 This estimate takes into account the 
more expensive antibiotic therapy required to treat multi-drug resistant pathogens, the increased 
duration of hospitalization, and the increased levels of care required by patients with multi-drug 
resistant pathogens.  However, this study only takes into account directly affected patients and 
does not attempt to estimate the economic burden of the ramifications of multi-drug resistance on 
the community36.   Nevertheless, the OTA’s estimated economic impact is considerable, and this 
cost is borne not only by the affected individual, but also by the hospital, the insurance pool, and 
the American taxpayer. 
The public health implications of multi-drug resistant gram-negative bacteremia will 
continue to grow unless and until new drugs are developed and better measures taken to stem the 
flow of resistant pathogens through the health care setting and into the community.  The lack of 
funding for the research and development of new antibiotics effective against gram-negative 
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organisms is troubling, and until new antibiotic development becomes a priority, multi-drug 
resistance will continue to grow and the associated increased morbidity and cost with it. 
 
Limitations 
 One limitation of this study was that it does not address whether patients with certain 
immunocompromising diseases such as diabetes mellitus or HIV suffer additional morbidity or 
mortality from multi-drug resistant pathogens.  This was not feasible in this study due to the low 
number of patients with HIV (9/600) and the fact that HgbA1C or another quantitative metric of 
diabetes status was not collected for study participants (patients were asked about their status on 
admission), so any measurement of the relationship between diabetes status and outcome would 
be difficult to measure or confirm. 
 An additional limitation of this study is the definition used for multi-drug resistance.  
Although the definition used was in accordance with the preponderance of the literature, several 
alternative definitions exist, including some who define multi-drug resistance as resistance to 2 
or more classes, 4 more or classes, and 5 or more classes.  Furthermore, the drugs used to 
represent each of the classes  - which were chosen based on the Duke University Hospital’s drug 
susceptibility reporting guidelines and preferred therapy guidelines - may not accurately reflect 
the drug susceptibilities of the entire class.   
 The accuracy with which the duration of hospitalization was calculated may pose an 
additional limitation to the study, as it does not take into account delays in discharge for other-
than-medical reasons.  Social circumstances or the unavailability of bed space at skilled nursing 
facilities may have delayed discharge for some patients, particularly those who required 
intensive care during their hospitalization. 
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 Finally, although the results of this study are fairly generalizable, the rates and patterns of 
antibiotic susceptibility vary throughout the nation.  Furthermore, the antibiotic susceptible and 
pathogen patterns in the setting in which this study took place – a US teaching hospital – may not 
represent the same patterns for other tertiary care centers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 33 of 38 
Conclusions 
 The data from this study shows that multi-drug resistance does not confer any additional 
mortality on patients with gram-negative bacteremia over those with pan-sensitive or ESBL-
producing pathogens.  However, multi-drug resistance is associated with a 1.8-fold increased rate 
of ICU admission and an 11.3-day increased duration of hospitalization over patients infected 
with a pan-sensitive pathogen.  In light of these findings, care should be taken to reduce the 
spread of multi-drug resistance and reduce the amount of time patients with multi-drug resistant 
gram-negative bacteremia have to wait before they are treated with effective antibiotic therapy.  
Further emphasis should be placed on the research and development of new antibiotics effective 
against gram-negative organisms in order to combat this re-emerging threat.  Additionally, future 
studies should be conducted to understand the effect of immunocompromising diseases such as 
HIV and diabetes mellitus on morbidity and mortality for each of the three sensitivity cohorts. 
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